TY - JOUR T1 - Economic impact of obstetric events on women of reproductive age living with psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis and psoriasis in Spain JO - Reumatología Clínica (English Edition) T2 - AU - Martínez,Nuria AU - Villar,Olga AU - Armijo,Onica AU - Castellanos,María AU - Marin Huarte,Natalia AU - Mareque,María AU - Casado,Miguel Ángel AU - Martínez-Barrio,Julia SN - 21735743 M3 - 10.1016/j.reumae.2021.04.001 DO - 10.1016/j.reumae.2021.04.001 UR - https://www.reumatologiaclinica.org/en-economic-impact-obstetric-events-on-articulo-S2173574321001076 AB - ObjectiveTo estimate the annual cost associated with obstetric events in women of reproductive age with immune-mediated inflammatory diseases, from the perspective of the National Healthcare System. MethodsA cost-analysis was developed to estimate the impact associated with obstetric events in women of reproductive age with psoriasis (PSO), psoriatic arthritis (PsA), rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA). The analysis considered complications during fertility and conception, in pregnancy and in the postpartum. All parameters were validated and agreed by a multidisciplinary expert panel. Unitary costs (€,2019) were obtained from national, local databases. ResultsDuring fertility and conception, an annual cost per patient of €229 was estimated for a preconception consultation in a patient with PSO, of €3642 for a preconception consultation in patients with PsA, RA and axSpA and €4339 for assisted reproduction. Women with complications in pregnancy had an annual cost per patient of €1214 for a miscarriage in the first trimester, €4419 for a late miscarriage in the second trimester, €11,260 for preeclampsia €3188 for restricted intrauterine growth and €12,131 for threat of premature delivery. In the postpartum, an annual cost per patient of €120,364, €44,709, and €5507 were estimated associated with admissions to neonatology of premature infants of <28, 28−32 and 33−37 weeks, respectively. ConclusionsThis analysis provides insight on the economic burden of complications associated with women of reproductive age for immune-mediated diseases (PSO, PsA, RA, axSpA). Individualization of treatment, additional and close monitoring may reduce the risk and burden of these complications. ER -